Introduction
============

Hepatocellular carcinoma (HCC) is widely known for its high morbidity, high malignancy, and high tendency of metastasis and recurrence, but its mechanism is still unclear, leading it to pose a great threat to public health. Sub-Saharan Africa and Asia are found to be high-prevalence areas of HCC, with China alone accounting for nearly 50% of HCC cases worldwide. A recent study showed that there were 4,661,000 new HCC cases and 4,221,000 deaths in China during 2015.[@b1-ott-11-5591] In the last half century, studies in the field of epidemiology, etiology, and the basic diagnosis and treatment of HCC have made significant progress. The postoperative survival rate has risen to some degree as well. Nonetheless, the reality is that the prognosis of HCC is still very disappointing, and postoperative recurrence and metastasis rate at 5 years is still up to 60%--70%.[@b2-ott-11-5591],[@b3-ott-11-5591] At present, serum alpha-fetoprotein (AFP) remains the most widely used marker for HCC diagnosis, despite its relatively low sensitivity and specificity as well as common false-negative/-positive phenomena. A credible marker or index for early diagnosis and prognosis prediction is still absent in current clinical practice. A recent study suggested that serum AFP has little prognostic value in compensated cirrhosis patients with a single, small HCC.[@b4-ott-11-5591] Thus, a novel and accurate marker that may improve the postoperative surveillance of early HCC in clinical practice is highly desirable.

Accumulating evidence shows that a number of major inflammatory mediators may exert significant impact on the formation of tumor microenvironment and contribute to the progression of HCC, some of which may be promising biomarkers for the early diagnosis and prognostic prediction of HCC,[@b5-ott-11-5591]--[@b15-ott-11-5591] such as tumor necrosis factor-α, interleukin-6, intercellular adhesion molecule-1,[@b5-ott-11-5591],[@b6-ott-11-5591] neutrophil to lymphocyte ratio (NLR), which is a previous study of our group,[@b7-ott-11-5591]--[@b9-ott-11-5591] C-reactive protein (CRP),[@b10-ott-11-5591],[@b11-ott-11-5591] high-sensitivity C-reactive protein (Hs-CRP),[@b12-ott-11-5591]--[@b15-ott-11-5591] and systemic immune-inflammation index (SII).[@b16-ott-11-5591] Although these indicators may have some predictive power, we found that Hs-CRP to lymphocyte ratio (HCLR) may serve as a more optimized novel indicator for the prognosis of HCC in our previous study.

This study was designed to investigate the optimal cutoff value of HCLR with the best discriminatory ability and evaluate the prognostic power of HCLR in HCC patients who underwent surgical resection.

Patients and methods
====================

Patients and clinical data
--------------------------

From July 2004 to March 2009, 229 cases of patients who underwent hepatectomy at the Affiliated Hospital of Guilin Medical University (Guilin, People's Republic of China) were included in this study. The majority of the patients (132/229) had tumors larger than 5 cm, and 45 out of 229 had more than one tumor focus. Five of the patients with recurrence (95/229) were extrahepatic. All patients were diagnosed by clinical, serological examination, ultrasonography (US), magnetic resonance imaging, computerized tomography of the thorax and abdomen, and bone scintigraphy. All were verified by pathologic examination. More than 90% were Child--Pugh class A patients. In addition, all the patients underwent curative resection, which was defined as a complete resection of the tumor with a resection margin of at least 1 cm and no new lesions determined by two observations not less than 4 weeks apart.[@b17-ott-11-5591] Demographic characteristics, cirrhosis, hepatitis B surface antigen, tumor size, AFP, HCLR, complete blood count, albumin, globulin, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase (AST), alkaline phosphatase, and γ-glutamyl transpeptidase (γ-GT) are listed in [Table 1](#t1-ott-11-5591){ref-type="table"}. All methods were performed according to the Affiliated Hospital of Guilin Medical University's guidelines and regulations. This study conformed to the Declaration of Helsinki and has received approval from the research ethics committee of the Affiliated Hospital of Guilin Medical University. Written informed consent was obtained from all patients.

Surveillance after hepatic resection
------------------------------------

For the criteria for patients' inclusion and exclusion, we referred to our previous reports,[@b6-ott-11-5591],[@b9-ott-11-5591] as well as the content and requirements for the periodical follow-ups. Liver function tests, AFP levels, and US were regularly monitored every 2 months. A chest radiograph was taken every 6 months during the first two postoperative years and then every 3--6 months. All the patients had routine follow-ups. If the AFP level or US test was abnormal, a computerized tomography scan or magnetic resonance imaging was done immediately. Progression-free survival (PFS) was defined from the date of surgery to the date of recurrence, metastasis, death, or last follow-up, while the overall survival (OS) was defined from the date of surgery to the date of death or last follow-up.

Receiver operating characteristic (ROC) curve
---------------------------------------------

ROC, also called the sensitivity curve, is named for the same sensitivity of each point on the curve. The points are all the reactions on the same signal stimulation and are merely different results under two criteria. The false-positive rate functions as the horizontal axis of ROC and the true-positive rate as the vertical axis. The curve is concluded from the various results obtained from different criteria of the subjects under the given stimulus.

Selection of cutoff value
-------------------------

The cutoff value is the judgment standard, which is the boundary value between the positive and the negative values. ROC curve analysis was performed to determine the cutoff value of HCLR. The point with the highest sensitivity and specificity was selected as the optimal cutoff value. Discriminatory ability of using the optimal cutoff value was evaluated by the sensitivity, specificity, positive/negative predictive value, and positive/negative likelihood ratio. The area under ROC curve (AUC) was also calculated to assess the overall accuracy.

Statistical analysis
--------------------

Analyses for all statistics were performed using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) and MedCalc 11.3.0.0 (MedCalc Software, Ostend, Belgium). Data conforming to Gaussian distribution were expressed as the mean ± SD and assessed by independent *t*-test. Categorical data were compared by the Pearson's chi-squared test or the Fisher's exact test. The Kaplan--Meier method was used to calculate OS and PFS, and survival distributions were compared with the log-rank test. Univariate analysis and multivariate Cox proportional hazards regression models were performed to determine independent prognostic factors. *P*\<0.05 was considered significant.

Results
=======

The optimal cutoff value of HCLR
--------------------------------

The AUC of the HCLR was 0.791 (95% CI, 0.731--0.840) for predicting the prognosis in patients with HCC. Based on the ROC curve, the optimal cutoff value of preoperative HCLR level was 1.3, with a sensitivity of 75.5% and a specificity of 71.8% ([Figure 1](#f1-ott-11-5591){ref-type="fig"}; [Table 2](#t2-ott-11-5591){ref-type="table"}). The classification performance of other AUC resulted from previously published literature, such as Hs-CRP, NLR, and SII, which were also calculated and are shown in [Figure 1](#f1-ott-11-5591){ref-type="fig"} and [Table 2](#t2-ott-11-5591){ref-type="table"}, and the AUCs were 0.760 (95% CI, 0.700--0.814), 0.678 (95% CI, 0.613--0.738), and 0.676 (95% CI, 0.611--0.736), respectively. These results suggested that HCLR is more valuable than the other three indices or parameters in predicting the prognosis of HCC.

The relationship between preoperative HCLR level and clinical characteristics
-----------------------------------------------------------------------------

The relationships between preoperative HCLR level and clinicopathologic parameters of HCC patients were analyzed and are shown in [Table 3](#t3-ott-11-5591){ref-type="table"}. All cases were divided into two groups: the low HCLR level group (HCLR ≤1.3) and the high HCLR level group (HCLR \>1.3). Other clinical characteristics were dichotomized as shown in [Table 3](#t3-ott-11-5591){ref-type="table"}. The results suggested that positive relationships existed between HCLR level and large tumor size (\>5 cm) (*χ*^2^=20.85, *P*\<0.001), TNM III--IV stage (*χ*[@b2-ott-11-5591]=23.69, *P*\<0.001), microvascular invasion (*χ*[@b2-ott-11-5591]=14.43, *P*\<0.001), recurrence (*χ*[@b2-ott-11-5591]=6.85, *P*=0.009), and serum AST level (*χ*[@b2-ott-11-5591]=6.92, *P*=0.009). The strong correlations of TNM stage and tumor size in relation to HCLR level can be seen in [Figure 2A and B](#f2-ott-11-5591){ref-type="fig"}. As the TNM stage and size of tumor increased, the level of HCLR gradually increased as well (Spearman's correlation coefficient *r*=0.418, *P*\<0.001 and *r*=0.386, *P*\<0.001, respectively). However, no significant relationships were found with gender, age, hepatitis B surface antigen, tumor number, drinking, and serum AFP level (all *P*\>0.05).

Association of HCLR and AFP with postoperative OS and PFS
---------------------------------------------------------

Kaplan--Meier survival analysis showed that the HCLR \>1.3 group was significantly associated with poorer PFS and OS in 229 HCC patients ([Figure 3A and B](#f3-ott-11-5591){ref-type="fig"}). Median OS was 41.58 months in the HCLR \>1.3 group and 68.22 months in the HCLR ≤1.3 group (*P*\<0.0001), while median PFS was 31.85 and 60.77 months, respectively. Compared with the AFP ≤20 ng/mL group, the AFP \>20 ng/mL group was also associated with poorer PFS (*P*=0.002; [Figure 3C](#f3-ott-11-5591){ref-type="fig"}) and OS (*P*=0.004; [Figure 3D](#f3-ott-11-5591){ref-type="fig"}).

Furthermore, we analyzed the postoperative survival of HCC patients in different tumor size subgroups. In HCC patients with tumor size ≤5 cm group (n=92), mean PFS was 44.59 months in the HCLR \>1.3 group and 63.53 months in the HCLR ≤1.3 group (*P*\<0.0001, [Figure 4A](#f4-ott-11-5591){ref-type="fig"}), while the mean OS was 54.62 months and 70.53 months (*P*\<0.0001, [Figure 4B](#f4-ott-11-5591){ref-type="fig"}), respectively. However, there was no significant PFS ([Figure 4C](#f4-ott-11-5591){ref-type="fig"}) or OS ([Figure 4D](#f4-ott-11-5591){ref-type="fig"}) difference between the subgroup of AFP ≤20 ng/mL and \>20 ng/mL (all *P*\>0.05). In HCC patients with tumor size ≤ 3 cm group (n=41), the mean PFS was 47.67 months in the HCLR \>1.3 group and 68.82 months in the HCLR ≤1.3 group (*P*= 0.026, [Figure 5A](#f5-ott-11-5591){ref-type="fig"}), while the mean OS was 55.81 months and 73.65 months (*P*=0.009, [Figure 5B](#f5-ott-11-5591){ref-type="fig"}), respectively. Nevertheless, there was no significant PFS ([Figure 5C](#f5-ott-11-5591){ref-type="fig"}) or OS ([Figure 5D](#f5-ott-11-5591){ref-type="fig"}) difference between the subgroup of AFP ≤20 ng/mL and \>20 ng/mL (all *P*\>0.05) in HCC patients with tumor size ≤3 cm. These results suggest that HCLR level still has prognostic value in middle- and small-sized HCC patients.

Predictors of OS and PFS in the univariate and multivariate analyses
--------------------------------------------------------------------

The results of univariate analysis are shown in [Table 4](#t4-ott-11-5591){ref-type="table"}. With an unadjusted hazard ratio (HR) of 3.21 (95% CI, 2.24--4.60), HCLR \>1.3 was an important prognostic factor of poor OS. In addition, tumor size \>5 cm, TNM III--IV stage, microvascular invasion, serum AFP \>20 ng/mL, and serum AST \>40 U/L were also predictors of poor OS. After adjusting other statistically significant predictors, the seven factors mentioned above were assessed using the stepwise multivariate Cox proportional hazards model, and microvascular invasion, serum AST \>40 U/L, and HCLR \>1.3 remained to be significant independent predictors of shorter OS (HR, 95% CI, and *P*-value are listed in [Table 4](#t4-ott-11-5591){ref-type="table"}). Similarly, in the univariate analysis, tumor size \>5 cm, III--IV of TNM stage, microvascular invasion, serum AFP \>20 ng/mL, serum AST \>40 U/L, and HCLR \>1.3 were poor predictors of PFS. However, only serum AST \>40 U/L and HCLR \>1.3 were independent predictors of shorter PFS (HR, 95% CI, and *P*-value are listed in [Table 4](#t4-ott-11-5591){ref-type="table"}).

Discussion
==========

HCC is a multifactor and multistep malignant tumor that mostly develops slowly from liver cirrhosis, atypical hyperplasia (precancerous), and other chronic inflammation.[@b18-ott-11-5591],[@b19-ott-11-5591] The biological behaviors of tumor cells, such as proliferation, invasion, and necrosis, can damage the adjacent tissues and cells. These cells can release inflammatory mediators and lead to inflammation, which can accelerate tumor proliferation and invasion, resulting in an unfavorable prognosis. For instance, Hs-CRP is a sensitive acute phase reactive protein generated by the liver and is closely related with infection, inflammation, and injury in the body.[@b20-ott-11-5591],[@b21-ott-11-5591] It has a vital significance in assessing the prognosis of some malignant tumors such as gastric carcinoma,[@b22-ott-11-5591] metastatic colorectal cancer,[@b23-ott-11-5591] nasopharyngeal carcinoma,[@b24-ott-11-5591] breast cancer,[@b25-ott-11-5591] HCC,[@b12-ott-11-5591]--[@b15-ott-11-5591] and so on. In addition, lymphocytes measure the performance of the host immune response against cancer, and a relative lymphopenia may observably weaken the host's antitumor immunity.

Determining tumor markers in peripheral blood based on the "liquid biopsies" method for early diagnosis and prognostic prediction is followed in recent cancer studies.[@b26-ott-11-5591] As prognostic markers for HCC patients, Hs-CRP and lymphocyte count are highly popular among investigators. It is effortless for patients to carry out real-time and dynamic monitoring ascribed to the easy detection of Hs-CRP and lymphocyte count in peripheral blood. In this study, we demonstrated that the optimal cutoff value of HCLR level was 1.3 with relatively high sensitivity and specificity. The AUC of HCLR was found to be higher than those of Hs-CRP, NLR, and SII. These findings suggest that HCLR can be an eligible marker for clinical practice and predicting the prognosis for HCC patients. The study found that HCLR \>1.3 was a risk factor for poor survival after hepatectomy. Meanwhile, elevated HCLR was positively related with large tumor size (\>5 cm), clinical TNM stage (III--IV), recurrence, micro-vascular invasion, and AST level (\>40 U/L). These results suggest that elevated HCLR may be associated with HCC biological aggressiveness, with persistence of microscopic tumor foci after surgery and with poor prognosis.

The univariate analysis showed that tumor size \>5 cm, TNM III--IV stage, microvascular invasion, AFP \>20 ng/mL, AST \>40 U/L, and HCLR \>1.3 were predictors of OS and PFS. The multivariate Cox regression analysis revealed that AST \>40 U/L and HCLR \>1.3 were independent predictors of OS and PFS, while microvascular invasion was an independent predictor for OS only. Some factors have shown their predictive ability to predict the prognosis of liver cancer in univariate analysis, but not in multivariate Cox regression analysis, and many previous researches have considered these variables as a predictor of prognosis of liver cancer. For example, high AFP level, tumor size \>5 cm, and TNM III--IV stage were considered as risk factors for recurrence and survival time after hepatectomy in some studies.[@b27-ott-11-5591]--[@b29-ott-11-5591]

Recently, accumulating evidence has shown that serum AFP level has limited predictive ability in patients with small HCCs.[@b4-ott-11-5591],[@b30-ott-11-5591] Consistent with previous reports, our results also indicated that serum AFP level had no prognostic role in HCC patients with tumor size ≤5 and ≤3 cm. Encouragingly, this study demonstrated that the HCLR level still had a significant prognostic value in the subgroups of middle and small tumor size. Therefore, HCLR may be a very good surveillance tool to predict the prognosis for early HCC patients.

Conclusion
==========

Our research suggests that an elevated HCLR level (HCLR \>1.3) is an independent predictor of OS and PFS. Preoperative elevated HCLR can indirectly reflect an inflammatory situation of the whole body or cancer tissue in HCC patients and accelerate tumor cells invasion and metastasis. Therefore, further research on the cause and mechanism of hepatic inflammation may contribute greatly to the early diagnosis, treatment, and prevention of recurrence of HCC. It should be noted that HCLR is a typical inflammatory factor in routine clinical detection and is mostly used as an observation target for anti-inflammatory therapy. HCLR is rarely used for follow-up monitoring of cancer patients who had undergone surgical resection. The fact that the optimal cutoff value has not been figured out might account for this situation. Since this study is a retrospective analysis and the sample source is limited in one department, further study that involves specimens from multiple departments is of great significance. To better confirm the prognostic value of HCLR in clinical practice, a prospective study will be appreciated.
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![ROC curve analysis was performed to assess the prognostic value of preoperative HCLR.\
**Abbreviations:** AUC, area under the curve; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; ROC, receiver operating characteristic; SII, systemic immune-inflammation index; Hs-CRP, high-sensitivity C-reactive protein.](ott-11-5591Fig1){#f1-ott-11-5591}

![Box plots of HCLR levels according to the TNM stage (**A**) and TD (**B**).\
**Abbreviations:** HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; TD, tumor diameter; TNM, tumor, node and metastases.](ott-11-5591Fig2){#f2-ott-11-5591}

![The relationship of HCLR and AFP with PFS or OS in the overall population.\
**Notes:** (**A**, **B**) Kaplan--Meier analysis revealed significantly shorter PFS (**A**) and OS (**B**) in HCC patients with HCLR \>1.3 than in those with HCLR ≤1.3. (**C**, **D**) PFS (**C**) and OS (**D**) of HCC patients with AFP \>20 ng/mL were shorter than in those with AFP ≤20 ng/mL.\
**Abbreviations:** AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; OS, overall survival; PFS, progression-free survival.](ott-11-5591Fig3){#f3-ott-11-5591}

![The relationship of HCLR and AFP with PFS or OS in patients with tumor size ≤5 cm.\
**Notes:** (**A**, **B**) HCLR \>1.3 significantly correlated with shorter PFS (**A**) and OS (**B**) in patients with tumor size ≤5 cm. (**C**, **D**) There was no significant difference in PFS (**C**) or OS (**D**) between AFP ≤20 ng/mL group and AFP \>20 ng/mL group in patients with tumor size ≤5 cm.\
**Abbreviations:** AFP, alpha-fetoprotein; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; OS, overall survival; PFS, progression-free survival.](ott-11-5591Fig4){#f4-ott-11-5591}

![The relationship of HCLR and AFP with PFS or OS in patients with HCC ≤3 cm.\
**Notes:** (**A**, **B**) Kaplan--Meier analysis revealed significantly shorter PFS (**A**) and OS (**B**) in HCC ≤3 cm patients with HCLR \>1.3 than in those with HCLR ≤1.3. (**C**, **D**) There was no significant difference in PFS (**C**) or OS (**D**) in the subgroup with AFP level ≤20 or \>20 ng/mL in patients with tumor size ≤3 cm.\
**Abbreviations:** AFP, alpha-fetoprotein; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; OS, overall survival; PFS, progression-free survival; HCC, hepatocellular carcinoma.](ott-11-5591Fig5){#f5-ott-11-5591}

###### 

Clinical and biochemical data of examined patients

  Parameter                      Mean ± SD[a](#tfn1-ott-11-5591){ref-type="table-fn"}
  ------------------------------ ------------------------------------------------------
  Age (years)                    50.46±10.88
  Gender: female/male (n)        27/202
  Alcohol abuse: yes/no (n)      91/138
  Cirrhosis: yes/no (n)          217/12
  HBsAg: positive/negative (n)   191/38
  Tumor size (range, cm)         7.28±3.93
  AFP (ng/mL): median, range     123.4 (0.23--38,030.00)
  WBC (×10^9^/L)                 6.47±2.13
  LYMPH (×10^9^/L)               1.74±0.66
  Platelets (×10^9^/L)           189.75±80.21
  Albumin (g/L)                  37.89±4.56
  Globulin (g/L)                 32.35±5.99
  TB (μmol/L): median, range     12.8 (4.7--159.05)
  DB (μmol/L): median, range     5.04 (1.83--128.99)
  ALT (U/L)                      46.14±53.42
  AST (U/L)                      51.52±53.76
  ALP (U/L)                      99.50±70.59
  γ-GT (U/L): median, range      63.4 (15.1--689.0)
  HCLR level: median, range      2.07 (0.01--32.8)

**Note:**

Data presented as mean ± SD or others.

**Abbreviations:** γ-GT, γ-glutamyl transpeptidase; AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DB, direct bilirubin; HBsAg, hepatitis B surface antigen; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; LYMPH, lymphocyte count; TB, total bilirubin; WBC, white blood cell.

###### 

The accuracy of different indices or parameters in predicting the prognosis of HCC patients

  Group    Cutoff value   AUC            Sensitivity    Specificity    PPV            NPV
  -------- -------------- -------------- -------------- -------------- -------------- --------------
  HCLR     1.3            0.791          0.755          0.718          0.844          0.606
  95% CI                  0.731--0.840   0.678--0.821   0.609--0.807   0.772--0.901   0.501--0.706
  Hs-CRP   2.2            0.760          0.735          0.702          0.836          0.559
  95% CI                  0.700--0.814   0.659--0.803   0.585--0.802   0.761--0.893   0.452--0.662
  NLR      2.2            0.678          0.586          0.736          0.820          0.448
  95% CI                  0.613--0.738   0.502--0.667   0.631--0.833   0.735--0.887   0.361--0.539
  SII      416            0.676          0.556          0.751          0.818          0.446
  95% CI                  0.611--0.736   0.473--0.636   0.640--0.845   0.736--0.885   0.359--0.537

**Abbreviations:** AUC, area under the receiver operating characteristics curve; HCC, hepatocellular carcinoma; HCLR, Hs-CRP to lymphocyte ratio; Hs-CRP, high-sensitivity C-reactive protein; NLR, neutrophil to lymphocyte ratio; NPV, negative predictive value; PPV, positive predictive value; SII, systemic immune-inflammation index.

###### 

Correlation between the clinicopathologic variables and HCLR in HCC

  Clinical character       Clinical variable   No of patients   HCLR level   *χ*^2^       *P*-value   
  ------------------------ ------------------- ---------------- ------------ ------------ ----------- -------------
  Gender                   Female              27               10 (37.0)    17 (63.0)    0.162       0.687
  Male                     202                 83 (41.1)        119 (58.9)                            
  Age (years)              ≤55                 153              58 (37.9)    95 (62.1)    1.39        0.237
  \>55                     76                  35 (46.1)        41 (53.9)                             
  HBsAg                    Negative            38               13 (34.2)    25 (65.8)    0.77        0.379
  Positive                 191                 80 (41.9)        111 (58.1)                            
  Tumor size (range, cm)   ≤5                  92               54 (58.7)    38 (41.3)    20.85       \<**0.001**
  \>5                      137                 39 (28.5)        98 (71.5)                             
  Tumor number             Single              184              72 (39.1)    112 (60.9)   0.85        0.356
  Multiple                 45                  21 (46.7)        24 (53.3)                             
  Drinking                 Absent              138              59 (42.8)    79 (57.2)    0.661       0.416
  Present                  91                  34 (37.4)        57 (62.6)                             
  TNM stage                I--II               118              66 (55.9)    52 (44.1)    23.69       \<**0.001**
  III--IV                  111                 27 (24.3)        84 (75.7)                             
  Microvascular invasion   Absent              181              85 (47.0)    96 (53.0)    14.43       \<**0.001**
  Present                  48                  8 (16.7)         40 (83.3)                             
  Recurrence               Absent              134              64 (47.8)    70 (52.2)    6.85        **0.009**
  Present                  95                  29 (30.5)        66 (69.5)                             
  AFP (ng/mL)              ≤20                 88               41 (46.6)    47 (53.4)    2.11        0.146
  \>20                     141                 52 (36.9)        89 (63.1)                             
  AST (U/L)                ≤40                 139              66 (47.5)    73 (52.5)    6.92        **0.009**
  \>40                     90                  27 (30.0)        63 (70.0)                             

**Note:** Bold figures represent as statistically significant.

**Abbreviations:** AFP, alpha-fetoprotein; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; HCC, hepatocellular carcinoma; TNM, tumor-node-metastases.

###### 

Univariate and multivariate Cox regression analyses of the HCLR with clinicopathologic characteristics

  Variable                                      Univariate analysis   Multivariate analysis                                     
  --------------------------------------------- --------------------- ----------------------- ------------- ------ ------------ -------------
  Overall survival                                                                                                              
   Gender (male vs female)                      1.02                  0.62--1.66              0.944                             
   Age, years (\>55 vs ≤55)                     0.83                  0.59--1.17              0.290                             
   HBsAg (positive vs negative)                 0.82                  0.55--1.23              0.343                             
   Tumor size, cm (\>5 vs ≤5)                   2.27                  1.61--3.20              \<**0.001**   1.42   1.02--1.96   0.063
   Tumor number (multiple vs single)            1.01                  0.67--1.52              0.948                             
   Drinking (present vs absent)                 1.11                  0.81--1.53              0.497                             
   TNM stage (III--IV vs I--II)                 2.55                  1.85--3.52              \<**0.001**   1.26   0.84--1.90   0.264
   Microvascular invasion (present vs absent)   3.05                  2.12--4.37              \<**0.001**   2.13   1.38--3.29   **0.001**
   Recurrence (present vs absent)               0.98                  0.97--1.01              0.062                             
   AFP, ng/mL (\>20 vs ≤20)                     1.53                  1.09--2.13              **0.012**     1.21   0.86--1.71   0.257
   AST, U/L (\>40 vs ≤40)                       1.91                  1.38--2.62              \<**0.001**   1.67   1.19--2.34   **0.003**
  HCLR level (\>1.3 vs ≤1.3)                    3.21                  2.24--4.60              \<**0.001**   2.64   1.81--3.86   \<**0.001**
   Progression-free survival                                                                                                    
   Gender (male vs female)                      1.01                  0.61--1.63              0.983                             
   Age, years (\>55 vs ≤55)                     0.83                  0.59--1.17              0.288                             
   HBsAg (positive vs negative)                 0.86                  0.57--1.29              0.473                             
   Tumor size, cm (\>5 vs ≤5)                   2.04                  1.45--2.88              \<**0.001**   1.39   0.95--2.03   0.086
   Tumor number (multiple vs single)            1.04                  0.69--1.56              0.845                             
   Drinking (present vs absent)                 1.16                  0.85--1.60              0.340                             
   TNM stage (III--IV vs I--II)                 2.22                  1.61--3.06              \<**0.001**   1.17   0.77--1.77   0.458
   Microvascular invasion (present vs absent)   2.30                  1.61--3.28              \<**0.001**   1.39   0.91--2.12   0.127
   AFP, ng/mL (\>20 vs ≤20)                     1.61                  1.15--2.24              **0.005**     1.28   0.90--1.82   0.170
   AST, U/L (\>40 vs ≤40)                       1.94                  1.41--2.68              \<**0.001**   1.49   1.04--2.13   **0.028**
   HCLR level (\>1.3 vs ≤1.3)                   2.97                  2.07--4.26              \<**0.001**   2.36   1.61--3.45   \<**0.001**

**Note:** Bold figures represent as statistically significant.

**Abbreviations:** AFP, alpha-fetoprotein; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HCLR, high-sensitivity C-reactive protein to lymphocyte ratio; HR, hazard ratio; TNM, tumor, node and metastases.
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